Ani Pharmaceuticals Inc (ANIP): who owns it and who trades it
As of Nov 16, 2026, ANIP insiders reported 47 open-market sales worth $13.6M and no purchases in the last 12 months, with 45% of the sale value made under pre-set 10b5-1 plans. The largest seller was Nikhil Lalwani (CEO), with $5.4M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Ani Pharmaceuticals
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ANIP
305 funds and institutions reported ANIP shares worth $1.9B at the end of Q2 2026. The largest holder is BlackRock, Inc. with $245M.
10 largest owners, by value
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 2.96M | – | $245M | +8% |
| Soleus Capital Management, L.P. | 867,760 | – | $71.8M | +6% |
| Vanguard Capital Management LLC | 838,224 | – | $69.4M | +2% |
| State Street Corp | 831,647 | – | $68.9M | +8% |
| Tang Capital Management LLC | 707,500 | – | $58.6M | No change |
| Dimensional Fund Advisors LP | 623,463 | – | $51.6M | +17% |
| American Century Companies Inc | 574,474 | – | $47.6M | +200% |
| Arrowstreet Capital, Limited Partnership | 562,016 | – | $46.5M | -0% |
| Global Alpha Capital Management Ltd. | 558,003 | – | $46.2M | +54% |
| Geode Capital Management, LLC | 536,407 | – | $44.4M | +10% |
| Millennium Management LLC | 507,207 | – | $42M | -14% |
| Nuveen, LLC | 415,024 | – | $34.4M | +3% |
| Vanguard Portfolio Management LLC | 407,281 | – | $33.7M | +8% |
| Ranger Investment Management, L.P. | 343,150 | – | $28.4M | -5% |
| Deutsche Bank Ag\ | 323,443 | – | $26.8M | +1% |
| Invesco Ltd. | 309,233 | – | $25.6M | -5% |
| UBS Group AG | 297,539 | – | $24.6M | -40% |
| Kennedy Capital Management LLC | 295,938 | – | $24.5M | +1% |
| Ameriprise Financial Inc | 287,382 | – | $23.8M | +6% |
| Nomura Asset Management International Inc. | 287,206 | – | $23.8M | -0% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ANIP insiders reported $0 of open-market purchases and $13.6M of sales. 45% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Meredith Cook | Vice president | Sale plan | 500 | $70.80 | $35.4K | Form 4 |
| Oct 29, 2026 | Stephen P. Carey | CFO | Sale plan | 2,850 | $72.87 | $208K | Form 4 |
| Oct 15, 2026 | Nikhil Lalwani | CEO | Sale plan | 5,400 | $71.89 | $388K | Form 4 |
| Oct 13, 2026 | Meredith Cook | Vice president | Sale plan | 500 | $73.59 | $36.8K | Form 4 |
| Sep 29, 2026 | Stephen P. Carey | CFO | Sale plan | 2,850 | $73.00 | $208K | Form 4 |
| Sep 15, 2026 | Nikhil Lalwani | CEO | Sale plan | 5,400 | $71.00 | $383K | Form 4 |
| Sep 14, 2026 | Meredith Cook | Vice president | Sale plan | 500 | $70.79 | $35.4K | Form 4 |
| Sep 11, 2026 | Jeanne Thoma | Director | Sale plan | 1,000 | $71.53 | $71.5K | Form 4 |
| Aug 31, 2026 | Stephen P. Carey | CFO | Sale plan | 2,850 | $72.80 | $207K | Form 4 |
| Aug 25, 2026 | Nikhil Lalwani | CEO | Sale plan | 5,400 | $74.30 | $401K | Form 4 |
| Aug 13, 2026 | Meredith Cook | Vice president | Sale plan | 500 | $75.48 | $37.7K | Form 4 |
| Aug 10, 2026 | Ori Gutwerg | Vice president | Sale | 3,162 | $77.00 | $243K | Form 4 |
| Jul 29, 2026 | Stephen P. Carey | CFO | Sale plan | 2,850 | $81.36 | $232K | Form 4 |
| Jul 13, 2026 | Meredith Cook | Vice president | Sale plan | 500 | $81.84 | $40.9K | Form 4 |
| Jul 2, 2026 | Stephen P. Carey | CFO | Sale plan | 3,313 | $86.00 | $285K | Form 4 |
| Jun 29, 2026 | Stephen P. Carey | CFO | Sale plan | 2,850 | $84.12 | $240K | Form 4 |
| Jun 12, 2026 | Meredith Cook | Vice president | Sale plan | 500 | $82.03 | $41K | Form 4 |
| Jun 8, 2026 | Thomas Haughey | Director | Sale plan | 2,000 | $80.88 | $162K | Form 4 |
| Jun 5, 2026 | Stephen P. Carey | CFO | Sale plan | 3,312 | $80.00 | $265K | Form 4 |
| May 13, 2026 | Patrick D Walsh | Director | Sale | 10,000 | $80.63 | $806K | Form 4 |
| May 13, 2026 | Meredith Cook | Vice president | Sale plan | 500 | $78.16 | $39.1K | Form 4 |
| May 12, 2026 | Thomas Andrew Rowland | Vice president | Sale | 459 | $79.21 | $36.4K | Form 4 |
| May 12, 2026 | Ori Gutwerg | Vice president | Sale | 2,772 | $79.50 | $220K | Form 4 |
| May 11, 2026 | Patrick D Walsh | Director | Sale | 3,973 | $80.75 | $321K | Form 4 |
| May 11, 2026 | Nikhil Lalwani | CEO | Sale | 55,000 | $77.57 | $4.3M | Form 4 |
| Apr 13, 2026 | Meredith Cook | Vice president | Sale plan | 500 | $77.95 | $39K | Form 4 |
| Mar 13, 2026 | Christopher Mutz | HEAD OF RARE DISEASE | Sale plan | 3,162 | $71.64 | $227K | Form 4 |
| Mar 13, 2026 | Meredith Cook | Vice president | Sale plan | 500 | $72.62 | $36.3K | Form 4 |
| Mar 11, 2026 | Thomas Andrew Rowland | Vice president | Sale | 4,772 | $74.91 | $357K | Form 4 |
| Mar 9, 2026 | Christopher Mutz | HEAD OF RARE DISEASE | Sale plan | 3,602 | $74.18 | $267K | Form 4 |
| Mar 9, 2026 | Krista Davis | Vice president | Sale plan | 5,087 | $74.13 | $377K | Form 4 |
| Mar 6, 2026 | Christopher Mutz | HEAD OF RARE DISEASE | Sale plan | 2,121 | $74.22 | $157K | Form 4 |
| Mar 6, 2026 | Krista Davis | Vice president | Sale plan | 1,485 | $75.00 | $111K | Form 4 |
| Mar 5, 2026 | Stephen P. Carey | CFO | Sale | 4,000 | $75.56 | $302K | Form 4 |
| Mar 5, 2026 | Stephen P. Carey | CFO | Sale | 3,312 | $75.42 | $250K | Form 4 |
| Mar 3, 2026 | Ori Gutwerg | Vice president | Sale | 2,060 | $76.50 | $158K | Form 4 |
| Mar 3, 2026 | Patrick D Walsh | Director | Sale | 6,000 | $74.23 | $445K | Form 4 |
| Mar 2, 2026 | Christopher Mutz | HEAD OF RARE DISEASE | Sale plan | 417 | $74.00 | $30.9K | Form 4 |
| Feb 20, 2026 | Christopher Mutz | HEAD OF RARE DISEASE | Sale plan | 5,323 | $78.02 | $415K | Form 4 |
| Feb 20, 2026 | Krista Davis | Vice president | Sale plan | 1,730 | $77.99 | $135K | Form 4 |
| Feb 19, 2026 | Krista Davis | Vice president | Sale plan | 2,084 | $77.53 | $162K | Form 4 |
| Feb 13, 2026 | Meredith Cook | Vice president | Sale plan | 500 | $76.80 | $38.4K | Form 4 |
| Feb 12, 2026 | Christopher Mutz | HEAD OF RARE DISEASE | Sale plan | 7,032 | $76.55 | $538K | Form 4 |
| Jan 13, 2026 | Meredith Cook | Vice president | Sale plan | 500 | $84.33 | $42.2K | Form 4 |
| Dec 18, 2025 | Krista Davis | Vice president | Sale plan | 1,622 | $82.40 | $134K | Form 4 |
| Dec 12, 2025 | Meredith Cook | Vice president | Sale plan | 400 | $82.32 | $32.9K | Form 4 |
| Dec 5, 2025 | Renee P Tannenbaum | Director | Sale | 1,800 | $81.15 | $146K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Nikhil Lalwani | PRESIDENT & CEO, Director | – | $5.4M | Oct 15, 2026 |
| Stephen P. Carey | SVP & CFO | – | $2.2M | Oct 29, 2026 |
| Christopher Mutz | HEAD OF RARE DISEASE | – | $1.6M | Mar 13, 2026 |
| Patrick D Walsh | Director | – | $1.6M | May 13, 2026 |
| Krista Davis | SVP, CHIEF HR OFFICER | – | $919K | Mar 9, 2026 |
| Ori Gutwerg | SVP, GENERICS | – | $621K | Aug 10, 2026 |
| Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | – | $455K | Nov 13, 2026 |
| Thomas Andrew Rowland | SVP, HEAD - ESTABLISHED BRANDS | – | $394K | May 12, 2026 |
| Thomas Haughey | Director | – | $162K | Jun 8, 2026 |
| Renee P Tannenbaum | Director | – | $146K | Dec 5, 2025 |
| Jeanne Thoma | Director | – | $71.5K | Sep 11, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ANIP short interest
3.58M ANIP shares are sold short. Over the last 12 reports the number of shares short went down 1%.
As of Oct 30, 2026, 3.58M ANIP shares were sold short, up 3.2% from the report before. At the average daily volume of 301,720 shares, buying them all back would take about 11.9 trading days (days to cover).
Shares short
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.58M | – | +3% | 301,720 | 11.9 |
| Oct 15, 2026 | 3.47M | – | -1% | 343,760 | 10.1 |
| Sep 30, 2026 | 3.49M | – | +40% | 487,356 | 7.2 |
| Sep 15, 2026 | 2.49M | – | -26% | 334,880 | 7.4 |
| Aug 31, 2026 | 3.36M | – | -2% | 364,912 | 9.2 |
| Aug 14, 2026 | 3.42M | – | +47% | 464,263 | 7.4 |
| Jul 31, 2026 | 2.33M | – | -31% | 252,428 | 9.2 |
| Jul 15, 2026 | 3.37M | – | -2% | 307,319 | 11.0 |
| Jun 30, 2026 | 3.44M | – | +8% | 365,430 | 9.4 |
| Jun 15, 2026 | 3.20M | – | -4% | 293,393 | 10.9 |
| May 29, 2026 | 3.32M | – | -8% | 336,455 | 9.9 |
| May 15, 2026 | 3.62M | – | +2% | 469,503 | 7.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Ani Pharmaceuticals company events
Ani Pharmaceuticals filed 12 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, auditor). The latest was on Nov 5, 2026.
- Nov 5, 2026AgreementOn Novemb er 4, 2 026, ANI Pharmaceuticals, Inc. entered into a credit agreement relating to a 364-day senior bridge facility, with the lenders named therein and JPMorgan Chase Bank, N.A, as administrative agent. Filing
- Nov 5, 2026ResultsReleased financial results. Filing
- Aug 24, 2026LeadershipThe Board of Directors of ANI Pharmaceuticals, Inc. appointed Henry Gosebruch to serve on the Board as a director with a term expiring at the Company’s 2027 annual meeting of stockholders. Filing
- Aug 7, 2026ResultsReleased financial results. Filing
- May 21, 2026LeadershipANI Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders on May 21, 2026. Filing
- May 13, 2026AnnouncementShared information with investors. Filing
- May 8, 2026ResultsReleased financial results. Filing
- Apr 7, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
- Mar 3, 2026AnnouncementShared information with investors. Filing
- Feb 27, 2026ResultsReleased financial results. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Dec 1, 2025LeadershipPatrick D. Walsh notified the Company that he will not seek re-election as a director at the Company’s 2026 Annual Meeting of Stockholders, but will continue to serve as a director until the Annual Meeting. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Ani Pharmaceuticals financials
Famous investors that hold ANIP
3 of the 50 well-known investors we track reported holding ANIP in their latest 13F filing. The largest position is Israel Englander's, worth $17.7M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 243,146 | $17.7M | 0.0% | -52% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 109,331 | $7.9M | 0.0% | +14% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 18,000 | $1.3M | 0.0% | -72% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Ani Pharmaceuticals Inc (ANIP) stock
Who owns the most ANIP stock?
The largest reported owner of Ani Pharmaceuticals Inc (ANIP) is BlackRock, Inc.. In total, 305 funds and institutions reported holding ANIP at the end of Q2 2026. See the largest owners.
Are ANIP insiders buying or selling?
In the last 12 months, ANIP insiders reported no open-market purchases and 47 sales worth $13.6M. The latest trade was on Nov 13, 2026. See every trade.
What is the short interest in ANIP?
As of Oct 30, 2026, 3.58M ANIP shares were sold short, up 3.2% from the report before. At the average daily volume of 301,720 shares, buying them all back would take about 11.9 trading days (days to cover). See the history.
Which famous investors hold ANIP?
3 of the 50 well-known investors we track reported ANIP in their latest 13F filing, including Israel Englander, Ken Griffin, Jim Simons. The largest position is worth $17.7M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.